Aiphi Nguyen, PharmD, CEO & Co-Founder
Dr. Aiphi Nguyen has a twofold pharmaceutical and financial background and has more than 15 years combined experience. She held various positions in marketing and sales with Bristol Myers Squibb before steering in the investment bank sector where she served as a business and financial analyst consultant in the life sciences sector. Prior to Skymab, she had on her credit the creation of two successful companies (Etsi communication and dixhuit Production).
Dr. Aiphi Nguyen holds a Doctorate in Pharmacy of the University Claude Bernard, a MBA of IAE (Institut d’Administration des Entreprises from Sorbonne University), a master of science in Finance of ESCP Europe and Challenge Plus of HEC Startup Program.
Didier Boquet, PhD, Principal Scientist at CEA & Co-Founder
Dr. Didier BOQUET has an initial formation in molecular biology. He obtained its PhD in 1993 under the direction of Pr Axel Kahn and its accreditation to Supervise Research (HDR)in 2006 from Denis Diderot Paris University. Principal Investigator in CEA in the antibodies targeting GPCR and antibody engineering scientific fields for 25 years, he has published over 60 papers and patents in relation with the theranostic applications. Reviewer for scientific journals and expert for various public or private funds, he gives lectures on therapeutic antibodies at the Faculty of Medicine of Paris Saclay University.
Amaury Herbet, Engineer, at CEA & Co-Founder
Mr Amaury Herbet has a pharmaceutical engineering backgroung. His experience at Hoechst Marion Roussel and Genopoietic allows him to acquire strong knowledge in the field of preclinical studies. He joigned the CEA in 1998 and led numerous studies for the international pharmaceutical industry, as study director. In 2007, he chose to join an internationally renowned research team.
He is the co-author of 2 patent relative antibodies addressing endothelin receptors for therapeutic and diagnosis purposes. To date he has more than 20 years combined experience acquired in different field of expertise in cellular biology, mAbs production and in vivo preclinical models.
Henri Benech, PharmD, PhD, Co-Founder
Dr. Henri Benech is a pharmacist with a PhD in Pharmacology and an accreditation to supervise research (HDR) from Paris-Sud and Paris-Descartes Universities. He has worked for 20 years as a principal investigator in drug metabolism and pharmacokinetics at the CEA. He conducted researchers on fate of magnesium in human using stable isotopes, on intracellular pharmacology of anti-HIV drugs and he developed a metabolic diagnostic test for treatment individualization. Later, he moved to the Technological Transfer Office of its organization to develop the technological transfer and to set-up spin-off, with a high success rate.
Dr. Henri Benech is a co-founder of CERES Brain Therapeutics, a biotech company dedicated to development of the treatment for cerebral rare diseases where he serves as the COO. He is also a member of the French National Academy of Pharmacy and an expert in medicines pricing since he has been rapporteur at the French comity pricing medicine for 5 years.